Introduction {#s1}
============

The study of protein function often demands high quality plasmid clones that contain the relevant open reading frames (ORFs) in a format compatible with protein expression. Increasingly, high throughput methods have created the demand for clones that encode a class of proteins of interest or the entire proteome of a species. Functional studies rely on *in vivo* expression for phenotypic studies or expression and purification by various means for biochemical analysis. Utilizing recombinational cloning vectors and including only the coding sequences, with all untranslated sequences removed, ensures maximum flexibility, including protein expression in a broad experimental range with various tagging options for either end of the protein. In addition, to avoid erroneous or ambiguous results regarding the expressed proteins, it is important that the plasmids are clonal isolates that are fully sequence verified.

For many eukaryotic species, including humans, the number of protein coding sequences exceeds 15,000 genes, making the production of comprehensive sequence-verified ORF clone collections daunting and expensive. In fact, a complete set of source material for expressed genes in humans does not yet exist [@pone.0001528-Baross1]--[@pone.0001528-Pennisi1]. One strategy is for researchers to focus on (a) meaningful subset(s) of genes for functional studies relevant to the biological questions they wish to address. For a human ORF collection the criteria for selecting genes are mostly driven by researchers\' interest and clone availability, resulting often in either collections of special interest [@pone.0001528-Collins1] [@pone.0001528-Park1], or more 'random' lists of genes in collections (RZPD, Invitrogen).

In recent years, a publicly funded project, the Mammalian Gene Collection (MGC), aimed to create for multiple species, but especially for man and mouse, collections of well annotated, fully sequence validated cDNA clones [@pone.0001528-Strausberg1]. However, the MGC clones cannot easily be employed directly in functional proteomics experiments because they are in many different vector backbones and contain 5′ and 3′ untranslated sequences. On the other hand, because they are fully sequenced and well annotated, these clones provide an excellent starting point for creating ORF clones. At least one such ORF set has been made so far, although that set comprises pools of clones that are not sequence verified [@pone.0001528-Rual1] [@pone.0001528-Lamesch1] and thus has potential ambiguity. Currently, there are also four human ORF collections available from commercial distributors that were clonally isolated and at least partially sequence validated. The recently created ORFeome Collaboration (<http://www.orfeomecollaboration.org/>) [@pone.0001528-Temple1] is a project planned to bring to all researchers an ORF clone collection that provides at least one representative ORF clone for all human genes, similar in quality and scope to the MGC clones, with all clones being fully sequence validated.

A limitation of the recombinational cloning vectors used for these ORF clones is that each clone must be committed to one of two non-interchangeable formats: *closed* (with stop codon; can express native protein) or *fusion* (no stop codon; enables the addition of carboxyl-terminal fusion peptides). As each format has unique advantages not available for the other, the ideal collection would include both.

Previously we reported the production of two smaller human clone sets in the Creator™ system. One set focused on kinase genes, both well-studied as well as novel or hypothetical ones [@pone.0001528-Park1]; the other clone set covered over 1000 genes associated with breast cancer [@pone.0001528-Witt1], identified in publications using software developed in our group [@pone.0001528-Hu1]. Here we report the production and complete sequence validation of 7000 clones, HLFEX7000 (\>3400 unique human genes in two formats), and the distribution of these genes with respect to their relationship to disease and biological terms in publications in PubMed.

Results {#s2}
=======

Gene Selection {#s2a}
--------------

To make the most useful ORF clone set of the MGC clones, we wished to select an enriched set of genes that is of particular interest to both medicine and biology. In addition, we wished to exclude clones that corresponded to partial gene products and to eliminate redundancy. We first excluded the subset of all MGC clones where the CDS length was less than 90% of the length of the longest corresponding NCBI RefSeq sequence [@pone.0001528-Pruitt1]--[@pone.0001528-Pruitt3]. We then removed redundancy within the MGC clone set, and picked the clone closest to the longest reference sequence by CDS length as a best MGC representative for each gene. This reduced the number of candidate template clones from 13493 to 7992, representing 7992 genes.

Our discussions with researchers indicated that a focused set of genes in both formats (closed and fusion) would be of more value that a large set in only one format. To ensure that our final gene set (Supplementary [Table S1](#pone.0001528.s001){ref-type="supplementary-material"}) was enriched for genes related to human diseases without any specific bias, the candidate list was used to query MedGene [@pone.0001528-Hu1] for genes associated with about 4000 human diseases. As described, MedGene is an automated literature-mining tool, which comprehensively summarizes and estimates the relative strengths of all human gene-disease relationships reported in Medline/PubMed. The result of this query was compared with queries using either all unique genes represented in MGC or all ∼33,000 human genes listed at the time in LocusLink (2004, now: EntrezGene [@pone.0001528-Pruitt4]). As shown for a subset of diseases in [Figure 1](#pone-0001528-g001){ref-type="fig"}; [Table 1](#pone-0001528-t001){ref-type="table"} (complete list: Supplementary [Table S2](#pone.0001528.s002){ref-type="supplementary-material"}), the resulting target list: (a) was highly enriched for the presence of genes with published associations with a wide range of human diseases; (b) had a similar relative ratio among the various diseases to that of both the genome and the MGC; and (c) displayed a broad overlap among different diseases allowing multiple diseases to be addressed with this set of ORF clones.

![Genes associated with Disease Classes (MeSH) in Publications.\
The clone target list (HFLEX7000) was compared with all human genes (EntrezGene, 2004) and all genes represented by MGC (2004) with respect to published relationships of the genes to human diseases. The targeted genes reveal similar proportionality to the other gene lists but a general enrichment of genes related to diseases ([Table 1](#pone-0001528-t001){ref-type="table"}; Supplementary [Table S2](#pone.0001528.s002){ref-type="supplementary-material"}).](pone.0001528.g001){#pone-0001528-g001}

10.1371/journal.pone.0001528.t001

###### MeSH Term Analysis for Gene and Diseases Association in Publications; Examples

![](pone.0001528.t001){#pone-0001528-t001-1}

  Disease MeSH Term                                                  Genome   MGC    HFLEX7000   MGC/Genome   HFLEX7000/Genome   HFLEX7000/MGC                
  ----------------------------------------------------------------- -------- ------ ----------- ------------ ------------------ --------------- ------ ------ ------
  Neoplasms                                                           7614    23.0     3904         40.0            1884             56.4        1.74   2.45   1.41
  Pathological Conditions, Signs and Symptoms                         7464    22.5     3631         37.2            1775             53.2        1.65   2.36   1.43
  Nervous System Diseases                                             5600    16.9     2753         28.2            1366             40.9        1.67   2.42   1.45
  Congenital, Hereditary, and Neonatal Diseases and Abnormalities     5269    15.9     2599         26.6            1287             38.5        1.67   2.42   1.4
  Digestive System Diseases                                           4710    14.2     2465         25.2            1253             37.5        1.77   2.64   1.49
  Immune System Diseases                                              4583    13.8     2302         23.6            1170             35.0        1.70   2.53   1.49
  Skin and Connective Tissue Diseases                                 4386    13.2     2256         23.1            1192             35.7        1.74   2.70   1.55
  Urologic and Male Genital Diseases                                  4025    12.2     2103         21.5            1087             32.6        1.77   2.68   1.51
  Endocrine System Diseases                                           4016    12.1     2060         21.1            1047             31.4        1.74   2.59   1.49
  Cardiovascular Diseases                                             3969    12.0     2034         20.8            1031             30.9        1.74   2.58   1.48
  Hemic and Lymphatic Diseases                                        3956    11.9     2049         21.0            1026             30.7        1.76   2.57   1.47
  Female Genital Diseases and Pregnancy Complications                 3826    11.6     2011         20.6            1028             30.8        1.78   2.66   1.50
  Nutritional and Metabolic Diseases                                  3670    11.1     1897         19.4            955              28.6        1.75   2.58   1.47
  Respiratory Tract Diseases                                          3524    10.6     1808         18.5            944              28.3        1.74   2.66   1.53
  Musculoskeletal Diseases                                            3518    10.6     1751         17.9            913              27.3        1.69   2.57   1.53
  Disorders of Environmental Origin                                   3466    10.5     1809         18.5            935              28.0        1.77   2.68   1.51
  Virus Diseases                                                      2963    8.9      1527         15.6            804              24.1        1.75   2.69   1.54
  Mental Disorders                                                    2903    8.8      1451         14.8            785              23.5        1.69   2.68   1.58
  Bacterial Infections and Mycoses                                    2817    8.5      1441         14.7            754              22.6        1.73   2.65   1.53
  Eye Diseases                                                        2700    8.2      1318         13.5            709              21.2        1.65   2.60   1.57
  Stomatognathic Diseases                                             2101    6.3      1069         10.9            583              17.5        1.72   2.75   1.60
  Otorhinolaryngologic Diseases                                       1882    5.7       941         9.6             503              15.1        1.69   2.65   1.56
  Parasitic Diseases                                                  1739    5.3       918         9.4             493              14.8        1.79   2.81   1.57

Examples of MedGene analysis of disease term association with genes in PubMed, using either all human genes (2004), unique genes in MGC (2004), or HFLEX7000 (targets). Numerical values and percentiles of each class associated with genes are shown. Relative MeSH term associations in either MGC or HFLEX7000 to the genome, and in HFLEX7000 to MGC examine a potential bias in MGC or HFLEX7000 towards specific MeSH terms.

In addition to disease relationships, we expanded our evaluation to include other search terms relevant for biological research by employing a new database, BioGene, which is based on a similar concept to MedGene. Instead of disease terms, BioGene has a co-citation index for all human genes with all biological and chemical Medical Subject Heading (MeSH) classes (<http://www.nlm.nih.gov/mesh>), such as "lipids", "pain" and "tetrahydrofolates", and is available at <http://biogene.med.harvard.edu/BIOGENE/>. As shown in [Figure 2](#pone-0001528-g002){ref-type="fig"}; [Table 2](#pone-0001528-t002){ref-type="table"} for 34 biological MeSH classes (complete listing for all analyzed MeSH terms in Supplementary [Table S3](#pone.0001528.s003){ref-type="supplementary-material"}), the candidate list is enriched for genes linked to all biological MeSH terms in the literature, but proportional to that of the entire MGC clones and to the entire genome.

![Genes associated with Biological MeSH Terms in Publications.\
The clone target list (HFLEX7000) was compared with all human genes (EntrezGene, 2004) and all genes represented by MGC (2004) with respect to published relationships of the genes to all biological MeSH terms and MeSH nodes (34). The targeted genes reveal similar proportionality to the other gene lists but a general enrichment of genes related to MeSH terms ([Table 2](#pone-0001528-t002){ref-type="table"}; Supplementary [Table S3](#pone.0001528.s003){ref-type="supplementary-material"}).](pone.0001528.g002){#pone-0001528-g002}

10.1371/journal.pone.0001528.t002

###### Biological and Chemical MeSH Class Analysis for Genes Associated in Publications with MeSH Class; Examples

![](pone.0001528.t002){#pone-0001528-t002-2}

  Biological/Chemical MeSH Class    Genome   Genome   MGC     MGC    HFLEX7000   HFLEX7000   MGC/Genome   HFLEX 7000/MGC   HFLEX7000/Genome
  -------------------------------- -------- -------- ------ ------- ----------- ----------- ------------ ---------------- ------------------
  Transcription, Genetic             6625    20.01    3457   35.38     1707        51.12        1.77           1.45              2.56
  Recombinant Proteins               6454    19.49    3431   35.11     1697        50.82        1.80           1.45              2.61
  Cell Survival                      2912     8.79    1567   16.04      824        24.68        1.82           1.54              2.81
  Subcellular Fractions              2753     8.31    1590   16.27      785        23.51        1.96           1.44              2.83
  Cyclic AMP                         2429     7.34    1271   13.01      670        20.07        1.77           1.54              2.74
  Protein Kinases                    2391     7.22    1307   13.37      668        20.01        1.85           1.50              2.77
  Insulin                            2212     6.68    1157   11.84      613        18.36        1.77           1.55              2.75
  Mitosis                            1917     5.79    1073   10.98      554        16.59        1.90           1.51              2.87
  RNA Splicing                       1950     5.89    1075   11.00      553        16.56        1.87           1.51              2.81
  DNA Replication                    1988     6.00    1071   10.96      540        16.17        1.83           1.48              2.69
  Antigens, Neoplasm                 1786     5.39    930    9.52       509        15.24        1.76           1.60              2.83
  Drug Resistance                    1645     4.97    910    9.31       486        14.56        1.87           1.56              2.93
  Drug Interactions                  1642     4.96    863    8.83       457        13.69        1.78           1.55              2.76
  Cell Membrane Permeability         1195     3.61    669    6.85       365        10.93        1.90           1.60              3.03
  Staurosporine                      1012     3.06    570    5.83       331        9.91         1.91           1.70              3.24
  Synapses                           1128     3.41    581    5.95       312        9.34         1.75           1.57              2.74
  Lipoproteins                       1024     3.09    554    5.67       305        9.13         1.83           1.61              2.95
  Genes, Lethal                      1083     3.27    589    6.03       300        8.98         1.84           1.49              2.75
  Cell Extracts                      943      2.85    563    5.76       295        8.83         2.02           1.53              3.10
  Adenosine                          957      2.89    527    5.39       281        8.42         1.87           1.56              2.91
  Hormones                           976      2.95    499    5.11       271        8.12         1.73           1.59              2.75
  Anti-Inflammatory Agents           891      2.69    473    4.84       270        8.09         1.80           1.67              3.01
  Peptide Library                    718      2.17    419    4.29       245        7.34         1.98           1.71              3.38
  Microglia                          700      2.11    406    4.15       241        7.22         1.97           1.74              3.41
  Tamoxifen                          776      2.34    445    4.55       237        7.10         1.94           1.56              3.03
  Pain                               812      2.45    391    4.00       229        6.86         1.63           1.71              2.80
  Liver Regeneration                 694      2.10    419    4.29       227        6.80         2.05           1.59              3.24
  Aspirin                            643      1.94    351    3.59       194        5.81         1.85           1.62              2.99
  Nucleosomes                        612      1.85    359    3.67       194        5.81         1.99           1.58              3.14

Examples of BioGene analysis of biological and chemical MeSH class associations with genes in PubMed, using either all human genes (2004), unique genes in MGC (2004), or HFLEX7000 (targets). Numerical values and percentiles of each class associated with genes are shown (\#, %). Relative MeSH Class associations in either MGC or HFLEX7000 to the genome, and in HFLEX7000 to MGC examine a potential bias in MGC or HFLEX7000 towards specific MeSH terms.

Thus, the target set of 3557 genes had a similar overall distribution of genes as the MGC and the human genome, but in general has a higher representation of genes that have been linked to both diseases and biological terms in the literature.

Clone Production and Sequence Validation {#s2b}
----------------------------------------

### Production of Clone Collection {#s2b1}

We generated the ORF clones via a processing pipeline that relies heavily on the use of robotics and is supported by the FLEXGene LIMS to produce clones in a highly automated, efficient, and accurate manner as published previously [@pone.0001528-Park1], [@pone.0001528-Witt1], [@pone.0001528-Hu2], [@pone.0001528-Murthy1].

The process of converting MGC cDNA clones into ORF clones ([Figure 3](#pone-0001528-g003){ref-type="fig"}) was initiated by populating our production tracking database (FLEXGene) with the relevant MGC information, e.g. IMAGE ID, GI number, clone sequence, start/stop of CDS, CDS length, gene information, plate and position in IMAGE/MGC collection. All ORFs were normalized to start with ATG, and natural stop codons either to TAG, or, for the format without C-terminal stop, to TTG (Leu). PCR amplicons were gel purified and captured using the In-Fusion™ enzyme into a modified recombinational cloning vector, pGWNcoXho, which increased the efficiency of capturing DNA fragments larger than 1.5 kb [@pone.0001528-Hu2]. After transformation into *E. coli*, constructs were clonally selected and isolated. In total, we successfully produced clonal glycerol stocks for 3,528 of 3,557 targeted genes, an overall success rate of ∼98% ([Table 3](#pone-0001528-t003){ref-type="table"}).

![Workflow diagram of clone production.\
The entire production process from the design of primers to production of glycerol stocks is shown. The process started by identifying MGC clones in the available plates and then creating array files along with matching PCR primer order files that included two primers anchored at the 3′ end, one for each format. The primers were used to amplify the ORFs from the matching MGC clones. PCR products were monitored in agarose gels, and products were purified prior to capture via In-Fusion reaction. Competent bacterial strains were transformed with the reaction followed by the robotic isolation of 4 resulting colonies per format, which were used to prepare 15% glycerol stocks. Prior to sequencing a single isolate plate of 96 targets were created. As indicated, step specific results were stored in our LIMS.](pone.0001528.g003){#pone-0001528-g003}

10.1371/journal.pone.0001528.t003

###### Clone Production and Sequencing Summary

![](pone.0001528.t003){#pone-0001528-t003-3}

                                                             Type    Phase1 (1st isolate)   Phase2 (2nd isolate)        Total
  -------------------------------------------------------- -------- ---------------------- ---------------------- ------------------
  ORF Target                                                CLOSED           3557                   277                  3557
                                                            FUSION           3557                   327                  3557
  Avg ORF size and range (bp)                                ALL       1268 (99--4,785)      1491 (171--4,395)     1268 (99--4,785)
  Clones for sequence validation                            CLOSED           3535                   277                  3812
                                                            FUSION           3496                   327                  3823
  Number of reads                                            ALL            20672                   1957                22629
  Average number of reads per clone                          ALL             2.9                    3.2                  2.9
  Accepted clones                                           CLOSED        3240 (91%)             223 (81%)            3463 (91%)
                                                            FUSION        3242 (92%)             258 (79%)            3500 (92%)
                                                             ALL             6482                   481                  6963
  Accepted clone match perfect with reference                ALL             6226                   443              6669 (95.8%)
  Accepted clone with silent mutation(s) only                ALL              94                     13               107 (1.5%)
  Accepted clone with 1 mis-sense                            ALL             162                     25               187 (2.7%)
  Rejected clones                                            ALL           646 (9%)              119 (20%)            765 (10%)
  Clones rejected for linker changes                         ALL             158                     43               201 (26%)
  Clones rejected for cds changes (ins/del/nonsense/mis)     ALL             187                     48               235 (31%)
  Clones rejected for no/incomplete/wrong assembly           ALL             301                     28               329 (43%)
  Accepted ORFs                                             CLOSED        3097 (88%)             222 (80%)            3295 (93%)
                                                            FUSION        3075 (88%)             256 (78%)            3259 (92%)
                                                             ALL             3387                   453               3447 (97%)

### DNA sequence analysis and clone acceptance {#s2b2}

Based on a pilot study of 96 genes in which we sequenced all available isolates (4 closed and 4 fusion), we expected that 90% of the clones would yield a valid clone. Thus, it was most efficient to sequence a single isolate for each attempted clone format and return to evaluate additional isolates for any that failed. Clones were accepted if they had no truncation mutations, no frameshift mutations and no more than one single amino acid difference with the reference sequence. Clones with any nucleotide changes in the att- sequences were rejected, as changes in these regions could make it impossible to transfer the ORF into expression vectors ([Table 3](#pone-0001528-t003){ref-type="table"}).

All rejected clones were manually inspected including a BLAST-based comparison to GenBank/EMBL to assess whether the clone matched any other entry for this gene. This step helped to rescue some rejected clones which were found to be ultimately acceptable due to updated MGC sequence entries.

Consistent with the pilot study, 6963 (90%) of the sequenced clones were acceptable based on the above criteria, with the vast majority (6669, or 95.8%) matching exactly to the reference sequence ([Table 3](#pone-0001528-t003){ref-type="table"}, for complete listing of clones see Supplementary [Table S4](#pone.0001528.s004){ref-type="supplementary-material"}). There were 25 clones that had identical discrepancies in both formats (with and without stop codon). As the two formats were independently produced from the same source clone, this suggests that there may be mistakes in as many as 0.3% of MGC reference sequences.

Discussion {#s3}
==========

Starting from the MGC resource, we created protein expression ORF clones in two different formats for over 3400 human genes, HFLEX7000, making them the largest contribution of fully sequence verified ORF clones to the ORFeome Collaboration ([www.Orfeomecollaboration.org](http://www.Orfeomecollaboration.org) ). The selection criteria for this subset were based on a combination of publication records for the individual gene and their association with biological as well as human disease MeSH terms, as defined by two programs, MedGene and BioGene. We aimed to reflect within this subset a similar distribution as it was present in MGC or the genome, and not to create a functionally or disease specific subset.

To assure the quality of this cDNA clone collection, we fully sequence verified all clones. By employing the appropriate formatted clone, users can add peptide tags to either end of the expressed protein or express protein without any additional amino acids at all. This is important for application reasons, e.g., for some proteins, the C-terminal amino acids may be important functionally (PDZ domain [@pone.0001528-DeLosRios1]) requiring a translation stop at the natural position, whereas for other proteins the natural N-terminus is relevant (e.g., signal peptides for membrane protein trafficking [@pone.0001528-Harrison1], [@pone.0001528-Hegde1]). Some applications exploit the use of fusion tags at the C-terminus as an experimental readout (e.g., yeast two hybrid [@pone.0001528-Rual1]), or for capturing expressed proteins and confirming full length expression [@pone.0001528-Ramachandran1].

We targeted over 3500 unique genes and obtained a fully sequence validated ORF clone for 97% (\>3400) of the genes. The strategy of selecting only one clonal isolate per gene for sequencing successfully yielded 90% acceptable clones. This success rate dropped to 80% when second isolates of the failed clones were sequenced, raising questions about the likelihood of success of sequencing additional isolates for clones that failed after two attempts. Also, capture efficiency, as measured by the number of colonies after transformation, was not a predictor of eventual clone success; clones with either high or low colony count numbers were equally likely to be rejected at subsequent steps.

One set of troublesome ORFs identified during PCR and confirmed during sequencing revealed duplication of either the 5′ (near the ATG) or 3′ (near the stop codon) sequences used to design the PCR primer elsewhere in the clone. This led to inappropriate PCR priming and ultimately an inability to clone the gene. Any project using a similar strategy to convert MGC clones into ORF clones might find the same problems, and alternatives, e.g. restriction enzyme/ligation based or fragmented PCR cloning, should be considered for any such ORFs.

In summary, the clones from MGC provide an excellent resource for ORF clone production. The 97% success rate to produce fully sequence validated clones, of which 96% match perfectly to the template clone, underlines that this strategy is feasible in a cost effective manner. Together with our other human ORF sets, notably several hundred DNA binding proteins, over 500 kinases, 1000 breast cancer associated genes, this much broader collection of 3500 genes will be of great benefit to the research community.

As with all our sequence validated clone collections, human, yeast, or microorganism, the HFLEX7000 clones are available at <http://plasmid.hms.harvard.edu>. Furthermore, this collection as part of the global ORFeome Collaboration will be available from the ORFeome distributors (<http://www.orfeomecollaboration.org/>).

Materials and Methods {#s4}
=====================

ORF-specific primer design and strategic 96-well plate organization {#s4a}
-------------------------------------------------------------------

ORF sequences were parsed out in the FLEXGene LIMS from the information provided with each MGC clone, and primer sequences were designed using a nearest neighbor algorithm as described earlier [@pone.0001528-Park1], [@pone.0001528-Witt1], [@pone.0001528-Hu2], [@pone.0001528-Murthy1]. Natural stop codons were either normalized to TAG or replaced with TTG (Leu) in the final primer designs. In addition to ORF-specific, start and stop regions, the 5′ and 3′ primers included fixed sequences that correspond to partial att sequence-specific recombination recognition sites that flank the ORF in the resultant plasmid clones.

Details regarding amplification, purification and capture into a linear version of pDONR221 by In-fusion™ reaction were previously published [@pone.0001528-Hu2]; PCR success as measured as signal in agarose gels, and capture success as determined as colonies after transformation were stored in FLEXGene LIMS as reported elsewhere [@pone.0001528-Witt1], [@pone.0001528-Hu2], [@pone.0001528-Murthy1].

Clone isolation and production of glycerol stocks {#s4b}
-------------------------------------------------

Transformations into *E. coli* (DH5alpha, T1 resistant) were handled in 96-well plates, and robotically plated to 48-sector LB/agar dishes with the appropriate antibiotic selection and grown overnight at 37°C. Colonies were robotically visualized and counted, and single isolates from each sector were picked for inoculation into 1mL growth media (LB/antibiotic) using a customized Megapix robot (Genetix), and 96-well culture blocks were grown overnight at 37°C in the presence of appropriate antibiotic. Inoculated cultures were assayed for growth via OD~600~ measurement as a measure of transformation efficiency, and aliquots were stored as 15% glycerol stocks in 96-well plate format.

Sequence reactions {#s4c}
------------------

High-throughput sequencing was carried out on an Applied Biosystems (ABI) capillary sequencer using dye-terminator and fluorescent cycle sequencing with don3 (TCTTGTGCAATGTAACATCAG) and don5 (CGTTAACGCTAGCATGGA) primers. Raw sequence data were automatically analyzed for quality, vector and repeat content using the pregap4 tool of the Staden Software Package [@pone.0001528-Staden1]. Reads passing this initial quality control were automatically assembled (gap4 tool of the Staden Software Package). The primer walking method was used to finish insert sequencing, with primers automatically designed by PRIDE [@pone.0001528-Haas1]. Sequencing was finished when an overall sequence quality of phred40 for the insert sequence and the vector-insert transition was achieved.

Sequence Analysis Software {#s4d}
--------------------------

After the clone sequence was assembled in the Staten package, the assembled sequences were verified using in house developed software [@pone.0001528-Taycher1]. Clones with acceptable linker as well as CDS sequences were collected for distribution. Clones were not accepted if they had discrepancies leading to protein truncations, frame shifts, discrepancies in the linker regions, or more than two amino acid differences with the reference polypeptide. Sequences of all clones started and ended at the BsrGI restriction site (TGTACA) of the vector, allowing QC of in-frame analysis as well as intactness of att recombination sites. Only clones that failed the CDS region evaluation underwent BLAST search against all available GenBank records, and were re-evaluated using matching BLAST hits in pairwise alignments, allowing us to rescue ∼5% of the clones.
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